THE country wants to further expand its share of North America's health care outsourcing market, confident of its strengths ...

Hims & Hers is shutting down Apostrophe, the skincare company it acquired in 2021, after a tumultuous month for the public ...

Shares of Hims & Hers Health (NYSE: HIMS) sank 10.5% this week, according to data from S&P Global Market Intelligence. The ...

Hims & Hers Health stock drops over 20% after the FDA removes semaglutide from the shortage list. Novo Nordisk launches a ...

Andrew Dudum is making it abundantly clear Hims is a healthcare company, not a cosmetic wellness brand. Ms. Manuel is a foreign policy expert and former U.S. government official who specializes in ...

Hims & Hers Health shares jumped some 20% to a record high on Wednesday following the announcement that it acquired lab testing facility Trybe Labs.

Shares of Hims & Hers Health plunged Friday after the Food & Drug Administration said a shortage of the active ingredient in Novo Nordisk’s Wegovy and Ozempic has been resolved.

Many treatments are available, and with the popularity of online and mail-order services in recent years, two leaders are BlueChew and Hims. Both companies offer different ED treatments and a ...

We recently published an article titled Jim Cramer Discusses These 12 Stocks & Says Late Selloffs Are Deliberate. In this ...

RKLX, the Defiance Daily Target 2X Long RKLB ETF, seeks daily investment results that correspond to twice (200%) the daily percentage change of Rocket Lab, a company at the forefront of satellite ...

Although Hims & Hers is saying it will still make its own compounded GLP-1 drugs in 2025, it is up in the air whether the U.S. government or court systems will allow the company to sell these ...